SK50672005A3 - Prípravok imunoglobulínu a spôsob jeho prípravy - Google Patents

Prípravok imunoglobulínu a spôsob jeho prípravy Download PDF

Info

Publication number
SK50672005A3
SK50672005A3 SK5067-2005A SK50672005A SK50672005A3 SK 50672005 A3 SK50672005 A3 SK 50672005A3 SK 50672005 A SK50672005 A SK 50672005A SK 50672005 A3 SK50672005 A3 SK 50672005A3
Authority
SK
Slovakia
Prior art keywords
composition
polysorbate
amount
antibody
present
Prior art date
Application number
SK5067-2005A
Other languages
English (en)
Slovak (sk)
Inventor
David J. Burke
Shaun E. Buckley
Sherwood Russ Lehrman
Barbara Horsey O�Connor
James Callaway
Original Assignee
Elan Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK50672005(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharmaceuticals, Inc. filed Critical Elan Pharmaceuticals, Inc.
Publication of SK50672005A3 publication Critical patent/SK50672005A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK5067-2005A 2003-02-10 2004-02-09 Prípravok imunoglobulínu a spôsob jeho prípravy SK50672005A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
PCT/US2004/003873 WO2004071439A2 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
SK50672005A3 true SK50672005A3 (sk) 2006-03-02

Family

ID=32869424

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5067-2005A SK50672005A3 (sk) 2003-02-10 2004-02-09 Prípravok imunoglobulínu a spôsob jeho prípravy

Country Status (28)

Country Link
US (7) US20050053598A1 (https=)
EP (4) EP1592440A4 (https=)
JP (3) JP4728948B2 (https=)
KR (1) KR20050110628A (https=)
CN (2) CN103040732B (https=)
AR (1) AR043144A1 (https=)
AU (2) AU2004210679A1 (https=)
CA (1) CA2515444C (https=)
CL (1) CL2004000224A1 (https=)
CY (2) CY1120574T1 (https=)
DK (2) DK3417875T3 (https=)
ES (1) ES2819011T3 (https=)
HU (1) HUE051878T2 (https=)
IL (1) IL170008A (https=)
MX (1) MXPA05008409A (https=)
MY (1) MY162623A (https=)
NO (1) NO346070B1 (https=)
PE (1) PE20050190A1 (https=)
PT (2) PT2236154T (https=)
RU (1) RU2358763C2 (https=)
SI (2) SI2236154T1 (https=)
SK (1) SK50672005A3 (https=)
TR (1) TR201808801T4 (https=)
TW (1) TWI367766B (https=)
UA (1) UA82685C2 (https=)
UY (1) UY28184A1 (https=)
WO (1) WO2004071439A2 (https=)
ZA (1) ZA200506159B (https=)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PT1729810T (pt) * 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Métodos de redução da agregação de il-ira
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
JP5303792B2 (ja) * 2007-02-12 2013-10-02 ボウジベル，ラサアド 保存料を含まないスクラロース無菌溶液
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
CN101889209A (zh) * 2007-10-22 2010-11-17 贝克顿·迪金森公司 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法和用含蛋白质溶液的有机基聚硅氧烷涂布的医疗制品
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2010077045A2 (en) * 2008-12-29 2010-07-08 Samyang Corporation Pharmaceutical composition of lyophilized formulation and preparation method of the same
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
BRPI1011389A2 (pt) * 2009-04-17 2018-07-10 Biogen Idec Inc método para tratar a leucemia mielógena aguda (aml) em um paciente
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
MX2012003282A (es) * 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
JP2013507131A (ja) * 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2810731A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
HUE050713T2 (hu) 2010-10-25 2020-12-28 Biogen Ma Inc Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
SG190069A1 (en) 2010-11-11 2013-06-28 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EA201391515A1 (ru) * 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. Инактивированная вакцина вируса денге
CN113244374A (zh) * 2011-07-01 2021-08-13 生物基因Ma公司 无精氨酸的tnfr:fc-融合多肽组合物及使用方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
KR102372245B1 (ko) 2013-11-21 2022-03-08 젠맵 에이/에스 항체-약물 접합체 동결건조 제제
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017015198A1 (en) * 2015-07-17 2017-01-26 Coherus Biosciences, Inc. Stable aqeous formulations of natalizumab
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG11201805534TA (en) 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
CN107063940B (zh) 2016-02-10 2019-10-18 贝克顿迪金森法国公司 用于评价基于蛋白质的制剂的稳定性的方法
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
US12240875B2 (en) * 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP3761953A1 (en) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019251453A1 (en) 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
US12030948B2 (en) * 2018-04-10 2024-07-09 Dr. Reddy's Laboratories Limited Antibody formulation
AU2019251452A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12409221B2 (en) 2018-12-24 2025-09-09 Grand Theravac Life Sciences (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114126647A (zh) * 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
CA3142994A1 (en) * 2019-06-11 2020-12-17 Macrogenics, Inc Pharmaceutical formulations of bi-specific diabodies and use of the same
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114786724A (zh) * 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物
EP4096802A4 (en) * 2020-01-29 2024-07-03 Merck Sharp & Dohme LLC METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
WO2022101935A1 (en) * 2020-11-12 2022-05-19 Dr. Reddy’S Laboratories Limited Stable aqueous high concentration formulation of integrin antibody
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508132C3 (de) * 1974-03-08 1980-10-16 Teijin Ltd., Osaka (Japan) Verfahren zur Herstellung von Humanimmunglobulin-Derivaten und parenteral applizierbare Lösung hiervon
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
SK287902B6 (sk) * 2001-01-31 2012-03-02 Evonik Rohm Gmbh Multiparticulate drug form and method for the preparation thereof
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
WO2004100984A1 (en) 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
EP2170390B1 (en) 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations

Also Published As

Publication number Publication date
MY162623A (en) 2017-06-30
US20100021461A1 (en) 2010-01-28
CN1771053B (zh) 2012-10-03
EP2236154B1 (en) 2018-05-30
ES2819011T3 (es) 2021-04-14
NO346070B1 (no) 2022-01-31
DK3417875T3 (da) 2020-08-31
US20130071386A1 (en) 2013-03-21
DK2236154T3 (en) 2018-06-25
CN103040732A (zh) 2013-04-17
EP3417875A1 (en) 2018-12-26
EP2236154A1 (en) 2010-10-06
JP4728948B2 (ja) 2011-07-20
WO2004071439A3 (en) 2005-07-07
TW200505478A (en) 2005-02-16
SI3417875T1 (sl) 2021-01-29
HK1182021A1 (en) 2013-11-22
EP3417875B1 (en) 2020-06-17
EP3777880A1 (en) 2021-02-17
US8815236B2 (en) 2014-08-26
TWI367766B (en) 2012-07-11
JP2006517233A (ja) 2006-07-20
CA2515444A1 (en) 2004-08-26
WO2004071439A2 (en) 2004-08-26
AU2004210679A1 (en) 2004-08-26
SI2236154T1 (en) 2018-08-31
CN103040732B (zh) 2015-04-01
UY28184A1 (es) 2004-09-30
US20120328614A1 (en) 2012-12-27
US20210292419A1 (en) 2021-09-23
AU2010202254B2 (en) 2012-02-23
CA2515444C (en) 2014-04-01
CL2004000224A1 (es) 2005-01-21
IL170008A (en) 2015-05-31
PE20050190A1 (es) 2005-03-21
NO20054164L (no) 2005-09-07
TR201808801T4 (tr) 2018-07-23
PT3417875T (pt) 2020-08-24
US8900577B2 (en) 2014-12-02
US20050053598A1 (en) 2005-03-10
PT2236154T (pt) 2018-06-26
HUE051878T2 (hu) 2021-03-29
US20180194843A1 (en) 2018-07-12
AU2010202254A1 (en) 2010-06-24
JP2014028831A (ja) 2014-02-13
KR20050110628A (ko) 2005-11-23
UA82685C2 (uk) 2008-05-12
MXPA05008409A (es) 2005-10-05
ZA200506159B (en) 2006-10-25
CN1771053A (zh) 2006-05-10
AR043144A1 (es) 2005-07-20
US8349321B2 (en) 2013-01-08
US10954303B2 (en) 2021-03-23
CY1123667T1 (el) 2022-03-24
CY1120574T1 (el) 2019-07-10
EP1592440A4 (en) 2007-07-11
RU2358763C2 (ru) 2009-06-20
US20150044206A1 (en) 2015-02-12
EP1592440A2 (en) 2005-11-09
RU2005128280A (ru) 2006-06-10
JP2011088913A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
US10954303B2 (en) Immunoglobulin formulation and method of preparation thereof
ES2676544T3 (es) Formulación de inmunoglobulina y procedimiento de preparación de la misma
US20240409631A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
AU2012202845B2 (en) Immunoglobulin formulation and method of preparation thereof
HK40002246B (en) Immunoglobulin formulation and method of preparation thereof
HK40002246A (en) Immunoglobulin formulation and method of preparation thereof
HK1182021B (en) Immunoglobulin formulation and method of preparation thereof
HK1091397A (en) Immunoglobulin formulation and method of preparation thereof

Legal Events

Date Code Title Description
TA4A Addition of inventor(s)
PC4A Assignment and transfer of rights

Owner name: BIOGEN IDEC INTERNATIONAL HOLDING LTD., HAMILT, BM

Free format text: FORMER OWNER: ELAN PHARMACEUTICALS, INC., CAMBRIDGE, MA, US

Effective date: 20141030

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASSACHUSETTS, US

Free format text: FORMER OWNER: BIOGEN IDEC INTERNATIONAL HOLDING LTD., HAMILTON HM EX, BM

Effective date: 20141030

TE4A Change of owner's address

Owner name: ELAN PHARMACEUTICALS, INC., CAMBRIDGE, MA, US

Effective date: 20141030

FC9A Refused patent application